inFLUenza

National Influenza Strategy Group

HomeAbout NISGAbout InfluenzaWho is EligibleThe VaccinesFAQResourcesPandemicAntiviralsContacts
Last Updated: Thursday, 22 April 2010

ANTIVIRALS

Influenza 2010

Frontline health workers should wear a surgical or procedure mask for close contact in addition to standard precautions when examining a patient with flu-like symptoms.  Precautions should also be taken with regards to eye protection, gowns, gloves and appropriate ventilation when performing high-risk aerosol-generating procedures such as bronchoscopy.

2010 Clinical Guidance and access to National Reserve Antivirals

Guidance on the diagnosis and management of Pandemic (H1N1) 2009 in the Pandemic 'Management' phase, version 5 - updated 19/04/10 Ministry of Health

Antiviral datasheets
Tamiflu Datasheet
Relenza Datasheet - medsafe.govt.nz

Case Definitions for Pandemic Influenza H1N1
updated 19/04/10 Ministry of Health

The purpose of the case definitions below is to assist with:

  • Public health or infection control responses
  • National and international reporting

Ongoing surveillance will also pick up probable and confirmed cases, but has a greater emphasis on specific systems for influenza-like illness and hospitalisations for picking up resurgence and monitoring progression.

Confirmed case
A confirmed case of pandemic influenza A (H1N1) virus infection is defined as a person with laboratory confirmed pandemic influenza A (H1N1) virus infection by one or more of the following tests:

  • Real-time RT-PCR
  • Viral culture
  • Four-fold rise in pandemic influenza A (H1N1) virus specific antibodies

Probable case
A probable case of pandemic influenza A (H1N1) virus infection is defined as a person with an influenza like illness* who has a strong epidemiological link to a confirmed case or defined cluster.

Close contact
Close contact is defined as having cared for, lived with or had direct contact with respiratory secretions or bodily fluids of a probable or confirmed case.

*Influenza-like illness: (i) history of fever, chills and sweating or clinically documented fever 38°C plus (ii) cough or sore throat.

Ministry of Health website www.moh.govt.nz/moh.nsf/indexmh/influenza-a-h1n1-healthsector  

Adobe Reader 9
If you are unable to open any of the above please click here to down load the Adobe reader


Top  |  Home  |  Print Page

Immune Advisory Centre Fluvax®, Vaxigrip® & Influvac® are Prescription Medicines. Contain inactivated strains of influenza vaccine for the prevention of influenza Types A & B. Specific types to be notified. Fluvax® CSL Biotherapies, Auckland. Vaxigrip® Sanofi Pasteur, Marketed by sanofi-aventis, Auckland, Influvac® Solvay Pharmaceuticals, Australia. Please read the brochure or consent form and talk to your doctor about the benefits and any possible side effects. For More information ring 0800 466 863.
TAPS NA 9998
Copyright © 2005 Immunisation Advisory Centre. All Rights Reserved. Web design by Insight & CMS by DMD Internet. .